CoChat

Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging

Open access
Jiang, Yuanbing, Zhou, Xiaopu, Ip, Fanny C., Chan, Philip, Chen, Yu, Lai, Nicole C.H., Cheung, Kit, Lo, Ronnie M.N., Tong, Estella P.S., Wong, Bonnie W.Y., Chan, Andrew L.T., Mok, Vincent C.T., Kwok, Timothy C.Y., Mok, Kin Y., Hardy, John, Zetterberg, Henrik, Fu, Amy K.Y., Ip, Nancy Y. · 2022 · Alzheimer's & Dementia
Cited by 162

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Introduction: Blood proteins are emerging as candidate biomarkers for Alzheimer's disease (AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high‐performance, blood‐based test for AD. Methods: We quantified 1160 plasma proteins in a Hong Kong Chinese cohort by high‐throughput proximity extension assay and validated the results in an independent cohort. In subgroup analyses, plasma biomarkers for amyloid, tau, phosphorylated tau, and neurodegeneration were used as endophenotypes of AD. Results: We identified 429 proteins that were dysregulated in AD plasma. We selected 19 “hub proteins” representative of the AD plasma protein profile, which formed the basis of a scoring system that accurately classified clinical AD (area under the curve = 0.9690–0.9816) and associated endophenotypes. Moreover, specific hub proteins exhibit disease stage‐dependent dysregulation, which can delineate AD stages. Discussion: This study comprehensively profiled the AD plasma proteome and serves as a foundation for a high‐performance, blood‐based test for clinical AD screening and staging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12369

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 162

Metadata

Authors
Jiang, Y., Zhou, X., Ip, F. C., Chan, P., Chen, Y., Lai, N. C. H., Cheung, K., Lo, R. M. N., Tong, E. P. S., Wong, B. W. Y., Chan, A. L. T., Mok, V. C. T., Kwok, T. C. Y., Mok, K. Y., Hardy, J., Zetterberg, H., Fu, A. K. Y., & Ip, N. Y.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2021-05-25
Volume
18
Issue
1
Pages
88-102
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W3164268272
Cited by
162
References
34
FWCI
14.75
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging. https://app.cochat.ai/papers/10.1002/alz.12369
The paper
Jiang, Y., Zhou, X., Ip, F. C., Chan, P., Chen, Y., Lai, N. C. H., Cheung, K., Lo, R. M. N., Tong, E. P. S., Wong, B. W. Y., Chan, A. L. T., Mok, V. C. T., Kwok, T. C. Y., Mok, K. Y., Hardy, J., Zetterberg, H., Fu, A. K. Y., & Ip, N. Y. (2022). Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12369

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.